Clinical Trial

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Study acronym: INVEST-HD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Protocol Amendment History 7 changes
notable Trial sites expanded: 51 -> 60 locations 2026-08-12
notable Trial sites expanded: 41 -> 51 locations 2026-07-30
notable Trial sites expanded: 27 -> 41 locations 2026-07-14
notable Trial sites expanded: 24 -> 27 locations 2026-06-24
notable Trial sites expanded: 20 -> 24 locations 2026-06-23
notable Trial sites expanded: 13 -> 20 locations 2026-06-09
notable Trial sites expanded: 4 -> 10 locations 2026-05-01
Trial Details
NCT Number NCT07326709
Lead Sponsor Novartis Pharmaceuticals
Conditions Huntington Disease
Enrollment 770 participants
Start Date 2026-03-24
Primary Completion 2030-04-02 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11